Sol-gel technologies announces the commercial availability of twyneo®

Ness ziona, israel, april 14, 2022 (globe newswire) -- sol-gel technologies, ltd. (nasdaq: slgl), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that twyneo ® , a topical cream containing a fixed‑dose combination of tretinoin, 0.1%, and benzoyl peroxide (bpo), 3% for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, is now available for purchase by consumers who obtain a prescription from their physician. twyneo cream was approved by the u.s. food and drug administration on july 27, 2021 and is being commercialized in the u.s. by galderma. it is the first and only tretinoin and benzoyl peroxide (bpo) 2-in-1 combination ever approved by fda and has been proven to rapidly treat even moderate to severe facial acne.1
SLGL Ratings Summary
SLGL Quant Ranking